D. E. Shaw & Co., Inc. Blueprint Medicines Corp Transaction History

D. E. Shaw & Co., Inc.

$122 Billion
Q4 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Blueprint Medicines Corp stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 361,801 shares of BPMC stock, worth $31.1 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

361,801

Previous 255,690 41.5%

Holding current value

$31.1 Million

Previous $23.6 Million 33.48%

% of portfolio

0.03%

Previous 0.02%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$82.48 - $101.39 $8.75 Million - $10.8 Million	106,111 Added 41.5%	361,801 $31.6 Million
Q3 2024 Nov 14, 2024	SELL	$84.1 - $120.5 $3.95 Million - $5.66 Million	-46,945 Reduced 15.51%	255,690 $23.6 Million
Q2 2024 Aug 14, 2024	SELL	$85.18 - $108.78 $6.26 Million - $8 Million	-73,542 Reduced 19.55%	302,635 $32.6 Million
Q1 2024 May 15, 2024	BUY	$73.17 - $99.79 $1.97 Million - $2.68 Million	26,860 Added 7.69%	376,177 $35.7 Million
Q4 2023 Feb 14, 2024	BUY	$43.96 - $92.84 $14.7 Million - $31.1 Million	335,279 Added 2388.37%	349,317 $32.2 Million
Q3 2023 Nov 14, 2023	BUY	$46.9 - $66.0 $658,382 - $926,508	14,038 New	14,038 $704,000
Q1 2023 May 15, 2023	SELL	$37.97 - $50.0 $686,725 - $904,300	-18,086 Reduced 45.95%	21,270 $956,000
Q4 2022 Feb 14, 2023	BUY	$41.06 - $66.48 $320,555 - $519,009	7,807 Added 24.75%	39,356 $1.72 Million
Q3 2022 Nov 14, 2022	SELL	$49.93 - $77.7 $314,459 - $489,354	-6,298 Reduced 16.64%	31,549 $2.08 Million
Q2 2022 Aug 15, 2022	SELL	$45.23 - $70.15 $611,600 - $948,568	-13,522 Reduced 26.32%	37,847 $1.91 Million
Q1 2022 May 16, 2022	SELL	$54.1 - $110.08 $6.95 Million - $14.1 Million	-128,398 Reduced 71.42%	51,369 $3.28 Million
Q4 2021 Feb 14, 2022	SELL	$94.25 - $115.99 $2.58 Million - $3.18 Million	-27,382 Reduced 13.22%	179,767 $19.3 Million
Q3 2021 Nov 15, 2021	SELL	$80.98 - $109.47 $5.18 Million - $7 Million	-63,948 Reduced 23.59%	207,149 $21.3 Million
Q2 2021 Aug 16, 2021	BUY	$82.78 - $101.0 $1.11 Million - $1.35 Million	13,355 Added 5.18%	271,097 $23.8 Million
Q1 2021 May 17, 2021	SELL	$90.71 - $108.28 $1.8 Million - $2.15 Million	-19,892 Reduced 7.16%	257,742 $25.1 Million
Q4 2020 Feb 16, 2021	SELL	$92.08 - $124.48 $2.16 Million - $2.92 Million	-23,454 Reduced 7.79%	277,634 $31.1 Million
Q3 2020 Nov 16, 2020	BUY	$66.45 - $92.7 $17.5 Million - $24.4 Million	262,769 Added 685.74%	301,088 $27.9 Million
Q2 2020 Aug 14, 2020	SELL	$57.09 - $79.27 $6.08 Million - $8.44 Million	-106,462 Reduced 73.53%	38,319 $2.99 Million
Q1 2020 May 15, 2020	SELL	$48.11 - $82.22 $648,955 - $1.11 Million	-13,489 Reduced 8.52%	144,781 $8.47 Million
Q4 2019 Feb 14, 2020	BUY	$66.73 - $82.59 $3.16 Million - $3.91 Million	47,339 Added 42.67%	158,270 $12.7 Million
Q3 2019 Nov 14, 2019	SELL	$72.9 - $101.41 $9.37 Million - $13 Million	-128,502 Reduced 53.67%	110,931 $8.15 Million
Q2 2019 Aug 14, 2019	BUY	$73.54 - $97.8 $11.1 Million - $14.7 Million	150,365 Added 168.82%	239,433 $22.6 Million
Q1 2019 May 15, 2019	BUY	$48.7 - $86.6 $4.34 Million - $7.71 Million	89,068 New	89,068 $7.13 Million
Q2 2018 Aug 14, 2018	SELL	$60.96 - $101.18 $1.68 Million - $2.79 Million	-27,613 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$73.28 - $102.95 $2.02 Million - $2.84 Million	27,613 New	27,613 $2.53 Million

Others Institutions Holding BPMC

# of Institutions

385

Shares Held

61.5M

Call Options Held

1.6M

Put Options Held

1.41M

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.14B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account